S T A T E O F N E W Y O R K
________________________________________________________________________
10001
I N A S S E M B L Y
May 1, 2024
___________
Introduced by M. of A. KELLES -- read once and referred to the Committee
on Health
AN ACT to amend the public health law, in relation to establishing the
endocannabinoid system awareness program
THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:
Section 1. The public health law is amended by adding a new section
3309-c to read as follows:
§ 3309-C. ENDOCANNABINOID SYSTEM AWARENESS PROGRAM. 1. THERE IS HEREBY
ESTABLISHED WITHIN THE DEPARTMENT THE ENDOCANNABINOID SYSTEM AWARENESS
PROGRAM WHICH SHALL EDUCATE HEALTH CARE PRACTITIONERS REGARDING THE
ENDOCANNABINOID SYSTEM AND HOW IT INTERACTS WITH OTHER BODILY SYSTEMS.
2. THE COMMISSIONER, IN CONSULTATION WITH THE DEPARTMENT OF EDUCATION
AND THE OFFICE OF CANNABIS MANAGEMENT, SHALL ESTABLISH STANDARDS, REVIEW
AND APPROVE COURSE WORK OR TRAINING ON THE ENDOCANNABINOID SYSTEM, AND
PUBLISH INFORMATION RELATED TO SUCH STANDARDS, COURSE WORK OR TRAINING
ON THE DEPARTMENT'S WEBSITE. THE COMMISSIONER, THE DEPARTMENT OF EDUCA-
TION AND THE OFFICE OF CANNABIS MANAGEMENT MAY CONSIDER EXISTING COURSE
WORK OR TRAINING, INCLUDING COURSE WORK OR TRAINING DEVELOPED BY A
NATIONALLY RECOGNIZED HEALTH CARE PROFESSIONAL, SPECIALTY, PROVIDER
ASSOCIATION OR NATIONALLY RECOGNIZED PAIN MANAGEMENT ASSOCIATION, WHEN
ESTABLISHING SUCH STANDARDS AND REVIEWING OR APPROVING SUCH COURSE WORK
OR TRAINING.
3. THE COMMISSIONER SHALL SET THE FOLLOWING MINIMUM HOURS OF COURSE
WORK AND TRAINING REQUIRED TO SATISFACTORILY MEET THE CRITERIA ESTAB-
LISHED PURSUANT TO SUBDIVISION TWO OF THIS SECTION:
(A) EVERY PERSON LICENSED UNDER TITLE EIGHT OF THE EDUCATION LAW SHALL
ON OR BEFORE JULY FIRST, TWO THOUSAND TWENTY-FIVE AND ONCE EVERY THREE
YEARS THEREAFTER, COMPLETE THREE HOURS OF COURSE WORK OR TRAINING ON THE
ENDOCANNABINOID SYSTEM WHICH HAS BEEN APPROVED BY THE DEPARTMENT.
(B) EVERY PERSON WHO SHALL RECEIVE A LICENSE ON OR AFTER JULY FIRST,
TWO THOUSAND TWENTY-FIVE UNDER TITLE EIGHT OF THE EDUCATION LAW, AND
EVERY MEDICAL RESIDENT, SHALL COMPLETE SUCH COURSE WORK OR TRAINING
EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD14857-01-4
A. 10001 2
WITHIN ONE YEAR OF GAINING SUCH STATUS AND ONCE EVERY THREE YEARS THERE-
AFTER.
4. THE COMMISSION SHALL CONSIDER THE FOLLOWING COURSE WORK OR TRAINING
TOPICS AS SATISFACTORILY MEETING THE TRAINING STANDARDS ESTABLISHED
PURSUANT TO SUBDIVISION TWO OF THIS SECTION AND SHALL INCLUDE THE
FOLLOWING TOPICS AND ACCOMPANYING SUBTOPICS:
(A) THE ENDOCANNABINOID SYSTEM, INCLUDING THE FOLLOWING SUBTOPICS:
(I) THE HISTORY OF TETRAHYDROCANNABINOL (THC) PHARMACOLOGY;
(II) THE CLINICAL EFFECTS OF THE ENDOCANNABINOID SYSTEM;
(III) LIMITATIONS OF AVAILABLE RESEARCH ON THE ENDOCANNABINOID SYSTEM;
(IV) UNDERSTANDING HOW THE ENDOCANNABINOID SYSTEM IS DEPENDENT ON
LIPID-BASED PHARMACOKINETICS AND PHARMACODYNAMICS;
(V) THE COMPONENTS OF THE ENDOCANNABINOID SYSTEM;
(VI) SPECIFIC ENZYMES USED BY THE ENDOCANNABINOID SYSTEM;
(VII) LIGANDS OF THE ENDOCANNABINOID SYSTEM RECEPTORS;
(VIII) LIGANDS OF THE CB1 AND CB2 RECEPTORS;
(IX) DYNAMICS OF THE ENDOCANNABINOID SYSTEM RECEPTOR EXPRESSION;
(X) THE LOCATION AND FUNCTION OF CB1 RECEPTORS, AND HOW SUCH RECEPTORS
EXPRESS THEMSELVES IN BODILY SYSTEMS;
(XI) SPECIFIC IMMUNE SYSTEM FUNCTIONS OF THE ENDOCANNABINOID SYSTEM;
AND
(XII) SPECIFIC PHYSIOLOGIC FUNCTIONS RELATED TO THE ENDOCANNABINOID
SYSTEM;
(B) CANNABINOIDS, CHRONIC PAIN AND OPIOIDS, INCLUDING THE FOLLOWING
SUBTOPICS:
(I) COMPARISONS BETWEEN THE EFFICIENCY OF NON-OPIOID AND OPIOID DRUGS
FOR CHRONIC BACK PAIN;
(II) THE MAGNITUDE OF THE PRESCRIPTION OPIOID OVERDOSE EPIDEMIC;
(III) HOW CONCOMITANT USE OF OPIOIDS AND BENZODIAZEPINES HAVE ADVERSE
IMPACTS ON HEALTH;
(IV) THE MECHANISMS BY WHICH CANNABINOIDS IMPACT THE NOCICEPTION
SYSTEM AND SPASTICITY;
(V) RECEPTORS INVOLVED WITH CANNABINOID EFFECTS ON PAIN MODULATION;
(VI) GENERAL SAFETY AND ADVERSE EFFECTS BETWEEN OPIOIDS, NON-STEROIDAL
ANTI-INFLAMMATORY DRUGS, AND CANNABINOIDS;
(VII) COMMON CONDITIONS IN WHICH MEDICAL CANNABIS SHOULD BE RECOM-
MENDED;
(VIII) NEGATIVE SIDE EFFECTS OPIOID SPARING HELPS REDUCE;
(IX) THE ADDITION OF CANNABINOID MEDICATION TO CHRONIC OPIOID THERAPY;
AND
(X) WHICH FORM OF CANNABIS A PATIENT SHOULD USE WHEN TAPERING FROM A
SLOW-RELEASE OPIOID;
(C) PHARMACOGENETICS AND CANNABIS, INCLUDING THE FOLLOWING SUBTOPICS:
(I) HOW TO IDENTIFY PATIENT ACCESS ISSUES AND STRATEGIES ON HOW TO
EXPLAIN PHARMACOGENETICS ARE NO LONGER AS EXPENSIVE;
(II) DESCRIPTION OF THE VARIATION OF ALLELES;
(III) IDENTIFYING THE PRINCIPAL ORGAN RESPONSIBLE FOR METABOLIZING
MEDICATIONS;
(IV) THE IMPORTANCE OF HOW THC IS METABOLIZED;
(V) HOW CANNABINOIDS ACT AS DRUG METABOLIZING ENZYMES;
(VI) HOW CYTOCHROME P450 (CYP) MONOOXYGENASES ENZYMES INTERACT WITH A
COMPREHENSIVE METABOLIC PANEL AND THE LIVER;
(VII) HOW TO INTERPRET GENOTYPE INFORMATION FOR PATIENT CARE;
(VIII) THE CLINICAL APPLICATION OF CANNABIS WITH OPIOIDS;
(IX) WHICH CLINICAL CONDITIONS SUPPORT THE NEED FOR PROPOXYPHENE TEST-
ING;
A. 10001 3
(X) THE POTENTIAL RISK OF CANNABIS DEPENDENCY; AND
(XI) THE HISTORY OF PSYCHOSIS INDUCED BY THC USE; AND
(D) FOOD AND DRUG ADMINISTRATION (FDA) APPROVED CANNABINOID MEDICA-
TIONS, INCLUDING THE FOLLOWING SUBTOPICS:
(I) IDENTIFYING THE CURRENTLY APPROVED FDA CANNABINOID DRUGS;
(II) THE HISTORY BEHIND THE FIRST SYNTHETIC THC MEDICATIONS ORIGINALLY
APPROVED BY THE FDA TO TREAT CLINICAL CONDITIONS;
(III) THE CLINICAL CONDITIONS FOR WHICH THE FDA APPROVED THE PLANT
EXTRACT ISOLATE OF CBD;
(IV) THE TWO THOUSAND SEVENTEEN REPORT BY THE NATIONAL ACADEMIES OF
SCIENCES ON THE CLINICAL USE OF CANNABINOIDS;
(V) PHARMACOKINETICS OF NABILONE AND THC ANALOGUES SUCH AS DRONABINOL;
(VI) CONDITIONS THAT DRONABINOL HAVE BEEN USED FOR THAT ARE NOT FDA
APPROVED AND COMMON SIDE EFFECTS; AND
(VII) EDUCATION ON HOW NABIXIMOLS ARE ADMINISTERED.
5. EVERY PERSON LICENSED OR IN THE PROCESS OF BEING LICENSED PURSUANT
TO SUBDIVISION THREE OF THIS SECTION SHALL ATTEST TO THE DEPARTMENT THAT
SUCH LICENSED PERSON OR PERSON IN THE PROCESS OF BEING LICENSED SHALL
HAVE COMPLETED THE NECESSARY COURSE WORK OR TRAINING REQUIRED BY THIS
SECTION ON A FORM PRESCRIBED BY THE COMMISSIONER.
6. THE DEPARTMENT SHALL ESTABLISH A PROCEDURE FOR ALLOWING LICENSEES
AN EXEMPTION FROM THE REQUIREMENTS OF THIS SECTION IF ANY LICENSED
PERSON ESTABLISHES THAT:
(A) THE LICENSED PERSON OR PERSON IN THE PROCESS OF BEING LICENSED
CLEARLY DEMONSTRATES TO THE DEPARTMENT'S SATISFACTION THAT THERE WOULD
BE NO NEED FOR SUCH LICENSED PERSON TO COMPLETE SUCH COURSE WORK OR
TRAINING; OR
(B) THE LICENSED PERSON OR PERSON IN THE PROCESS OF BEING LICENSED
COMPLETED COURSE WORK OR TRAINING DEEMED BY THE DEPARTMENT TO BE EQUIV-
ALENT TO THE COURSE WORK OR TRAINING APPROVED BY THE DEPARTMENT PURSUANT
TO SUBDIVISION TWO OF THIS SECTION.
7. NOTHING IN THIS SECTION SHALL PRECLUDE SUCH COURSE WORK OR TRAINING
ABOUT THE ENDOCANNABINOID SYSTEM FROM COUNTING TOWARD THE CONTINUING
EDUCATION REQUIREMENTS UNDER TITLE EIGHT OF THE EDUCATION LAW OR THE
CONTINUING REQUIREMENTS OF A NATIONALLY ACCREDITED MEDICAL BOARD TO THE
EXTENT ACCEPTABLE TO SUCH BOARD.
§ 2. The public health law is amended by adding a new section 3309-d
to read as follows:
§ 3309-D. ENDOCANNABINOID SYSTEM WORK GROUP FOR PUBLIC AWARENESS. 1.
THE COMMISSIONER OF PUBLIC HEALTH SHALL ESTABLISH AN ENDOCANNABINOID
SYSTEM WORK GROUP (REFERRED TO IN THIS SECTION AS THE "WORK GROUP").
SUCH WORK GROUP SHALL BE ESTABLISHED NO LATER THAN ONE YEAR AFTER THE
EFFECTIVE DATE OF THIS SECTION. SUCH WORK GROUP SHALL BE COMPOSED OF
EXPERTS WITH SIGNIFICANT KNOWLEDGE AND EXPERTISE RELATED TO THE ENDOCAN-
NABINOID SYSTEM, AND SHALL INCLUDE, BUT NOT BE LIMITED TO, CONSUMER
ADVISORY ORGANIZATIONS, HEALTH CARE PRACTITIONERS AND PROVIDERS, AND
PHARMACISTS AND PHARMACIES. MEMBERS OF SUCH WORK GROUP SHALL RECEIVE NO
COMPENSATION FOR THEIR SERVICES BUT SHALL BE ALLOWED THE ACTUAL AND
NECESSARY EXPENSES IN THE PERFORMANCE OF THEIR DUTIES PURSUANT TO THIS
SECTION.
2. THE WORK GROUP SHALL REPORT TO THE COMMISSIONER REGARDING THE
DEVELOPMENT OF RECOMMENDATIONS AND MODEL COURSES FOR CONTINUING MEDICAL
EDUCATION, REFRESHER COURSES, AND OTHER TRAINING MATERIALS FOR LICENSED
HEALTH CARE PROFESSIONALS RELATED TO THE ENDOCANNABINOID SYSTEM AND
CONTINUING EDUCATION REQUIREMENTS FOR PHARMACISTS RELATED TO THE ENDO-
CANNABINOID SYSTEM. SUCH RECOMMENDATIONS, MODEL COURSES, AND OTHER
A. 10001 4
TRAINING MATERIALS SHALL BE SUBMITTED TO THE COMMISSIONER, WHO SHALL
MAKE SUCH INFORMATION AVAILABLE FOR USE IN MEDICAL EDUCATION, RESIDENCY
PROGRAMS, FELLOWSHIP PROGRAMS, AND IN CONTINUING MEDICATION EDUCATION
PROGRAMS NO LATER THAN JANUARY FIRST, TWO YEARS AFTER THE EFFECTIVE DATE
OF THIS SECTION.
3. NO LATER THAN JANUARY FIRST, TWO YEARS AFTER THE EFFECTIVE DATE OF
THIS SECTION, THE WORK GROUP SHALL PROVIDE OUTREACH AND ASSISTANCE TO
HEALTH CARE PROFESSIONAL ORGANIZATIONS TO ENCOURAGE AND FACILITATE
CONTINUING MEDICAL EDUCATION TRAINING PROGRAMS FOR THEIR MEMBERS RELATED
TO THE ENDOCANNABINOID SYSTEM.
4. ON OR BEFORE SEPTEMBER FIRST, ONE YEAR AFTER THE EFFECTIVE DATE OF
THIS SECTION, THE COMMISSIONER OF HEALTH, IN CONSULTATION WITH THE
OFFICE OF CANNABIS MANAGEMENT, THE COMMISSIONER OF THE DEPARTMENT OF
EDUCATION, AND THE EXECUTIVE SECRETARY OF THE STATE BOARD OF PHARMACY,
SHALL HAVE THE AUTHORITY TO ADD ADDITIONAL MEMBERS TO THE WORK GROUP AS
APPROPRIATE TO PROVIDE GUIDANCE IN FURTHERANCE OF THE IMPLEMENTATION OF
THE WORK GROUP'S EFFORTS.
5. THE WORK GROUP SHALL BE RESPONSIBLE FOR DEVELOPING A PUBLIC AWARE-
NESS CAMPAIGN TO BE PROVIDED TO THE COMMISSIONER OF HEALTH, SUCH PUBLIC
AWARENESS CAMPAIGN SHALL INCLUDE INFORMATION AND RESOURCES ABOUT THE
ENDOCANNABINOID SYSTEM AND BE AVAILABLE ON THE DEPARTMENT OF HEALTH'S
WEBSITE WITH ACTIVE WEBLINKS TO MATERIALS FOR THE PUBLIC TO ACCESS.
6. THE COMMISSIONER SHALL HAVE THE POWER TO DIRECT THE WORK GROUP TO
CONSIDER AND RESEARCH ANY ISSUE ON THE ENDOCANNABINOID SYSTEM DEEMED
RELEVANT UNDER THEIR DISCRETION.
7. THE COMMISSIONER SHALL REPORT TO THE GOVERNOR, THE TEMPORARY PRESI-
DENT OF THE SENATE AND THE SPEAKER OF THE ASSEMBLY NO LATER THAN TWO
YEARS AFTER THE EFFECTIVE DATE OF THIS SECTION AND ANNUALLY THEREAFTER
ON THE WORK GROUP'S FINDINGS IN REGARD TO ITS CONTINUING EDUCATION
EFFORTS, THE STATUS OF THE PUBLIC AWARENESS CAMPAIGN, AND ANY OTHER
ISSUES DEEMED RELEVANT BY THE COMMISSIONER ON THE ENDOCANNABINOID
SYSTEM.
§ 3. This act shall take effect immediately.